Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies With First - in - Class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis Now Available at Reportsandreports
GBI Research’s report, “Musculoskeletal Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First-in-class Mechanism of Action to Increase Treatment Options in Osteoporosis and Rheumatoid Arthritis", provides in-depth analysis of unmet need
View full press release